Hengrui Launches Apatinib With Echoes Of Icotinib Approach
This article was originally published in PharmAsia News
Executive Summary
Jiangsu Hengrui is going all out for its apatinib launch, combining a follow-on study and patient assistance with post-marketing research and local reimbursement talks. Will the comprehensive strategy work for the gastric cancer drug like it has for Betta in the lung cancer market?